Author: Newsdesk

Posted on

Verrica Pharmaceuticals Announces Receipt of Final FDA Minutes Following Type A Meeting Regarding Resubmission of the NDA for VP-102 in Molluscum

– Verrica reaffirms expectation to resubmit its New Drug Application for VP-102 for the treatment of molluscum in the first quarter of 2021 –

WEST CHESTER, Penn., Nov. 17, 2020 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it has received the final meeting minutes from the U.S. Food and Drug Administration (FDA) following the Company’s recent Type A meeting to discuss the steps required for resubmission of the New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum).

VP-102 is a first-in-class, proprietary drug-device combination for the treatment of molluscum, a viral skin disease affecting approximately six million people, primarily children, in the United States. There are currently no FDA-approved treatments for molluscum. In July, the Company announced that it had received a Complete Response Letter from the FDA requesting additional Chemistry, Manufacturing and Controls (CMC) information as well as Human Factors validation.

“We are encouraged by our productive discussion with the FDA and the FDA’s written meeting minutes, which reflect alignment on the steps to address the CMC issues raised in the CRL as well as the path forward for resubmission of the NDA and the potential approval of VP-102 to treat patients with molluscum,” said Ted White, President and Chief Executive Officer, Verrica. “In addition, our Human Factors study protocol has been reviewed by the FDA and we are preparing to complete that study by the end of the year. We are pleased to reaffirm our expectation to resubmit the NDA for VP-102 pursuant to the statutory 505(b)(1) regulatory pathway in the first quarter of 2021.”

This news follows Verrica’s recent announcement of positive results for VP-102 for the treatment of external genital warts (EGW) in the Phase 2 CARE-1 trial. As previously announced, Verrica intends to request an End-of-Phase 2 meeting with the FDA for VP-102 in EGW in the first quarter of 2021.

About Verrica Pharmaceuticals Inc.

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. The Company’s late-stage product candidate, VP-102, is a potential first-in-class drug-device combination product containing a topical therapy for the treatment of molluscum contagiosum. In addition, Verrica has successfully completed a Phase 2 study of VP-102 for the treatment of common warts and a Phase 2 study of VP-102 for the treatment of external genital warts. The Company is also developing VP-103, its third cantharidin-based product candidate, for the treatment of plantar warts. Verrica submitted an NDA for VP-102 for the treatment of molluscum in September 2019. A Complete Response Letter was received from the FDA regarding the NDA for VP-102 on July 13, 2020. In October 2020, Verrica participated in a Type A meeting with the FDA. Verrica expects to resubmit its New Drug Application for VP-102 for the treatment of molluscum in the first quarter of 2021. If approved, VP-102 will be marketed in the United States under the conditionally accepted brand name YCANTH™. For more information, visit www.verrica.com.

Forward-Looking Statement
s

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include expectations regarding the Company’s expectations with regard to its interactions and communications with the FDA, the timing for its resubmission of the NDA for VP-102 in the first quarter of 2021, the potential approval of the NDA for VP-102 following resubmission, the potential benefits and potential commercialization of VP-102 for the treatment of molluscum, if approved, and the potential benefits and clinical development plan for VP-102 for the treatment of EGW. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the drug development process and the regulatory approval process, Verrica’s reliance on third parties over which it may not always have full control, uncertainties related to the COVID-19 pandemic and other risks and uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year ended December 31, 2019, Verrica’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, and other filings Verrica makes with the U.S. Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

A. Brian Davis

Chief Financial Officer
484.453.3300 ext. 103
[email protected]

William Windham

Solebury Trout
646.378.2946
[email protected]

Media:

Zara Lockshin

Solebury Trout
646.378.2960
[email protected]



Posted on

VitalHub Announces Licensing Deal with East Suffolk and North Essex NHS Foundation Trust

TORONTO, Nov. 17, 2020 (GLOBE NEWSWIRE) — VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce an expansion licensing transaction of newly-acquired subsidiary Intouch with Health’s (“Intouch”) suite of patient flow and operational visibility solutions to East Suffolk and North Essex NHS Foundation Trust (the “Trust” or “ESNEFT”).

East Suffolk and North Essex NHS Foundation Trust provides hospital and community health care services for Colchester, Ipswich and local areas, including Aldeburgh, Clacton, Halstead, Harwich and Felixstowe community hospitals and Bluebird Lodge near Ipswich, and is the largest NHS organization in the region. This licensing transaction comes as a result of the Trust’s need for a cohesive pre-operative solution to load balance capacity and demand and manage flow across various sites and departments. The Trust had previously been an Intouch client, having licensed Intouch’s Check-in and Flow Manager solutions. As a result of the success of the initial implementation of these products, the Trust has completed an expansion licensing deal with the Company, to acquire the Synopsis Home and Synopsis iQ suite of solutions.

Through the implementation of these solutions, the Trust will be able to meaningfully advance its digital transformation aspirations, intended toward enabling the integration of care systems across facilities to provide enhanced care delivery and patient outcomes. Specifically, the use of the Synopsis product suite will afford the Trust an ability to promote high quality, dynamic outpatient services which accommodate socially distanced care delivery.

The COVID-19 crisis has made it necessary for hospitals to have as many patients stay at home as possible, which must be balanced with the need to continue to carry out urgent elective surgery. Remote pre-operative assessments satisfy that need by supporting social distancing and infection control. Synopsis Home enables trusts to pre-assess at least 60% of their patients remotely. The Trust is following the lead of the Worcestershire Acute Hospitals NHS Trust, who have pre-assessed 100% of their patients remotely since March.

The transition to a virtual clinic format will facilitate a reduction in their requirement of patients to attend hospitals for consultations, improving capacity and load balancing, patient convenience, and the overall care delivery process. These improvements will also extend to long-term care patients who will be proactively managed in their homes, affording improved levels of communication while reducing pressures on clinicians and Trust resources.

The Trust has licensed the multiple-award-winning Synopsis iQ product, providing the ability to share comprehensive pre-operative information with providers, allowing them to care for patients in a blended and seamless manner, managing, on the same integrated platform, those patients who present remotely for consultation alongside those who physical present at one of their hospital sites. Alongside Synopsis iQ, the Trust also plans to license Synopsis Home, enabling patients to complete their pre-operative health questionnaire remotely.

“With this deal, we continue to expand our footprint and reach across the National Health Service. We are delighted that our customers continue to find immense value in our products, especially during a time when minimizing the number of patients physically present in the hospital is vital,” said VitalHub CEO Dan Matlow. “We look forward to continuing to provide best-in-class patient flow and operational visibility solutions to healthcare organizations on a global basis, both during the pandemic and afterward, as we lead the charge in offering solutions that maximize health system efficiency, benefiting all of the systems, health professionals, and the patients.”

ABOUT
EAST SUFFOLK AND NORTH ESSEX NHS FOUNDATION TRUST

East Suffolk and North Essex NHS Foundation Trust delivers hospital and community health care services for Colchester, Ipswich, and surrounding areas as the largest NHS organization in the region. The Trust was formed on 1 July 2018 through the merger of Colchester Hospital University NHS Foundation Trust and The Ipswich Hospital NHS Trust, and now services Colchester and Ipswich hospitals, Aldeburgh, Clacton, Halstead, Harwich and Felixstowe community hospitals, Bluebird Lodge near Ipswich, and delivers community services in Suffolk.

ABOUT VITALHUB

Software for Health and Human Services providers designed to simplify the user experience & optimize outcomes.

VitalHub provides technology to Health and Human Services providers including; Hospitals, Regional Health Authorities, Mental Health, Long Term Care, Home Health, Community and Social Services. VitalHub solutions span the categories of Electronic Health Record (EHR), Case Management, Care Coordination, Patient Flow & Operational Visibility, and DOCit Mobile Apps.

The Company has a robust two-pronged growth strategy, targeting organic growth opportunities within its product suite, and pursuing an aggressive M&A plan. Currently, VitalHub serves 275+ clients across Canada, USA, UK, Australia, Qatar, and Latvia. VitalHub is based in Toronto, Canada, with an offshore development hub in Sri Lanka. The Company is publicly traded on the TSX Venture Exchange under the symbol “VHI”.

CAUTIONARY STATEMENT

This press release includes forward-looking statements regarding the Corporation and its business, which may include, but is not limited to, statements with respect to the appointment of a new directors. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity and are based on assumptions and subject to risks and uncertainties. Although the management of each entity believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including risks regarding the technology industry, failure to obtain regulatory or shareholder approvals, market conditions, economic factors, the equity markets generally and risks associated with growth and competition. Although the Corporation has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Corporation undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

CONTACT INFORMATION

Dan Matlow
Chief Executive Officer, Director
(416) 727-9061
[email protected]



Posted on

Progenity to Present at 2020 San Antonio Breast Cancer Virtual Symposium

SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) — Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, will be presenting at the San Antonio Breast Cancer Virtual Symposium (SABCS) set to take place December 8-11, 2020.

The data presented will be a part of the event’s Spotlight Session Poster Presenters. Details of the presentation are as follows:

Title –
Describing the cancer spectrum in families with CHEK2 pathogenic and likely pathogenic variants by mutation type

Authors – Julia G Moroney, MS, CGC, and Michele S. Basiliere, MS, CGC
Poster number – PS8-18
Date and time – Wednesday, December 9, 2020: 8:00 AM CT

SABCS anticipates publishing abstracts in late November 2020 and posters on December 9, 2020. The poster presentation will also be made available on the Progenity website following the conference.

About Progenity

Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies. For additional information about Progenity, please visit the company’s website at www.progenity.com.

Investor Contact:

Robert Uhl
Managing Director, Westwicke ICR
[email protected]
(619) 228-5886

Media Contact:

Kate Blom-Lowery
CG Life
media@progenity.com
(619)743-6294



Posted on

Thryv, Inc. to Participate in Stephens Annual Investment Conference 2020

Dallas, Nov. 17, 2020 (GLOBE NEWSWIRE) — Thryv Holdings, Inc. (NASDAQ:THRY), the provider of Thryv® software, the end-to-end client experience platform for small businesses, today announced that CEO and President Joe Walsh will participate in a virtual fireside chat discussion at the Stephens Annual Investment Conference 2020 on November 19 at 3 p.m. ET.

A live webcast of the Stephens conference presentation will be available on the Thryv investor relations website at investor.thryv.com. An archived replay will be made available for a limited time at the same location following the event. 

About Thryv Holdings, Inc.

The company owns the easy-to-use Thryv® end-to-end customer experience software built for small business that helps over 40,000 SaaS clients with the daily demands of running a business. With Thryv, they can get the job, manage the job and get credit. Thryv’s award-winning platform provides modernized business functions, allowing small-to-medium-sized businesses (SMB) to reach more customers, stay organized, get paid faster and generate reviews. These include building a digital customer database, automated marketing through email and text, updating business listings across the internet, scheduling online appointments, sending notifications and reminders, managing ratings and reviews, generating estimates and invoices and processing payments.

Thryv supports franchise operators and multi-location business owners with Hub by Thryv™, a software console that enables businesses managers to oversee their operations using the Thryv software.

Thryv also connects local businesses to consumer services through our search, display and social media management products, our print directories featuring The Real Yellow Pages® tagline, and our local search portals, which operate under the DexKnows.com®, Superpages.com® and Yellowpages.com URLs and reach some 35 million monthly visitors. For more information about the company, visit thryv.com.

Thryv delivers business services to more than 360,000 SMBs across America that enable them to compete and win in today’s economy.      

Learn more about Thryv on LinkedIn and Medium.

 

Media Contact:

Paige Blankenship

Thryv, Inc.

972.453.3012

[email protected]

 

Investor Contact:

Cameron Lessard 


Thryv, Inc.
    

214.773.7022 

[email protected]   

 

KJ Christopher

Thryv, Inc.

972.453.7068

[email protected]

 

###



Paige Blankenship
Thryv, Inc.
972.453.3012
[email protected]

Posted on

CloudMD to Present at Upcoming Investor Conferences

VANCOUVER, British Columbia, Nov. 17, 2020 (GLOBE NEWSWIRE) — CloudMD Software & Services Inc. (TSXV: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the “Company” or “CloudMD”), a telemedicine company seeking to revolutionize the delivery of healthcare to patients, is pleased to announce that executives from the Company’s management team will be participating in the following upcoming investor conferences:

Canaccord
Genuity
Health and Wellness
Virtual Conference
,

November 23, 2020

  • Dr. Essam Hamza, CEO, will be participating in the Digital Health and Telemedicine Panel at 9 a.m. EST
  • Karen Adams, Chief Health Innovation Officer, will be participating in the Mental Health Services Panel at 11a.m. EST

To register for this virtual conference, please contact your Canaccord representative.

Desjardins Digital Healthcare Conference,

November 24, 2020

  • Dr. Essam Hamza, CEO will be presenting the Company and business at 1:45 p.m. EST

To register for this conference, please contact your Desjardins representative.

About CloudMD Software & Services

CloudMD is digitizing the delivery of healthcare by providing a patient centric approach, with an emphasis on continuity of care. The Company offers SAAS based health technology solutions to healthcare providers across North America and has developed proprietary technology that delivers quality healthcare through a holistic offering including hybrid primary care clinics, specialist care, telemedicine, mental health support, educational resources and artificial intelligence (AI). CloudMD currently services a combined ecosystem of over 500 clinics, almost 4000 licensed practitioners and 8 million patient charts across North America.

ON BEHALF OF THE BOARD OF DIRECTORS

“Dr. Essam Hamza, MD”

Chief Executive Officer

FOR ADDITIONAL INFORMATION CONTACT:

Julia Becker

VP, Investor Relations

Email: [email protected]

Forward Looking Statements

This news release contains forward-looking statements that are based on CloudMD’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business. Although CloudMD believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and CloudMD undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

The
TSX Venture
Exchange does not accept responsibility for the adequacy or accuracy of this release.



Posted on

Salarius Pharmaceuticals to Participate in A.G.P.’s Virtual Healthcare Symposium

HOUSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors and other cancers, today announced its chief executive officer, David Arthur, will participate in A.G.P.’s Virtual Healthcare Symposium on Thursday, November 19, 2020.

Mr. Arthur will host virtual one-on-one meetings with investors registered to attend the conference to discuss Salarius’ business, recent achievements, and anticipated clinical milestones. The Company’s lead drug candidate, seclidemstat, is an oral medication that inhibits lysine-specific demethylase 1 (LSD1), an enzyme that is over-produced in some cancers and can promote disease progression. Seclidemstat is being studied in two ongoing Phase 1/2 clinical trials — the first, in patients with relapsed or refractory Ewing sarcoma, a deadly bone and soft tissue cancer primarily diagnosed in children and young adults, and the second, in patients with advanced solid tumors (AST). Early clinical data suggests that that patients can be treated at dose levels that produce drug concentrations similar to concentrations where seclidemstat showed anti-tumor activity in preclinical models.

Salarius previously disclosed that a refractory Ewing sarcoma patient treated with seclidemstat for six months demonstrated a reduction of over 80% in prospectively defined target lesions. Target lesions generally represent a patient’s largest measurable tumors.

For questions and inquiries regarding the conference or to register for a one-on-one meeting, please contact a registered A.G.P. representative or email A.G.P. Events at [email protected].

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients that need them the most. Salarius’ lead candidate, seclidemstat, is being studied as a potential treatment for pediatric cancers, solid tumors and other cancers with limited treatment options. Seclidemstat is currently in a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma, for which it has received Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration. Salarius is also developing seclidemstat for several cancers with high unmet medical need, with a second Phase 1/2 clinical study in advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius previously disclosed that a refractory Ewing sarcoma patient treated with seclidemstat for six months demonstrated a reduction of over 80% in prospectively defined target lesions. Target lesions generally represent a patient’s largest measurable tumors. However, at eight weeks, an increase in non-target lesions resulted in an overall patient classification of progressive disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST). Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and was also the recipient of an $18.7 million Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit salariuspharma.com or follow the Company on Twitter and LinkedIn.

Forward-Looking Statements 

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These forward-looking statements may be identified by terms such as “will,” “could,” “believe,” “plan,” “will,” “expect,” “target,” and similar terms or expressions or the negative thereof. Examples of such statements include, but are not limited to, the potential of seclidemstat as a potential treatment for Ewing-related sarcomas; the ability of seclidemstat to demonstrate drug activity; the ability of and degree to which seclidemstat could have a significant impact on the treatment of Ewing sarcoma, as well as other sarcomas with related Ewing sarcoma biology; and the safety profile of seclidemstat in any indication. Salarius may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in the forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements are subject to risks and uncertainties which could cause actual results and performance to differ materially from those discussed in the forward-looking statements. These risks and uncertainties include, but are not limited to, the following: the ability of Salarius to raise additional capital to meet its business operational needs and to achieve its business objectives and strategy; Salarius’ ability to project future capital needs and cash utilization; available sources of cash, including from CPRIT and its equity line; future clinical trial results; that the results of studies and clinical trials may not be predictive of future clinical trial results; the sufficiency of Salarius’ intellectual property protection; risks related to the drug development and the regulatory approval process; the competitive landscape and other industry-related risks; market conditions which may impact the ability of Salarius access capital under its equity line; the possibility of unexpected expenses or other uses of Salarius’ cash resources; and other risks described in Salarius’ filings with the Securities and Exchange Commission, including those under the heading “Risk Factors.” The forward-looking statements contained in this press release speak only as of the date of this press release and are based on management’s assumptions and estimates as of such date. Salarius disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.

Contact

Tiberend Strategic Advisors, Inc.
Maureen McEnroe, CFA/Miriam Miller (investors)
(212) 375-2664 / 2694
[email protected]
[email protected]

Johanna Bennett (media)
(212) 375-2686 
[email protected]



Posted on

SG Blocks Joint Venture Partnership Clarity Mobile Ventures to Provide Interim Coronavirus Tests for Passengers and Employees at Los Angeles International Airport (LAX)

SG Blocks Joint Venture Partnership Clarity Mobile Ventures to Provide Interim Coronavirus Tests for Passengers and Employees at Los Angeles International Airport (LAX)

LOS ANGELES–(BUSINESS WIRE)–
SG Blocks, Inc. (NASDAQ: SGBX) (“SG Blocks” or the “Company”), a leading designer, innovator and fabricator of container-based structures, announced today that its Clarity Mobile Venture (“CMV”) partnership with Clarity Lab Solutions will be implementing an interim COVID-19 testing solution at Los Angeles International Airport (LAX) in which PCR tests with results available within 24 hours will be accessible, in addition to other rapid coronavirus tests.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201117005539/en/

Planned COVID-19 testing locations at Los Angeles International Airport. (Photo: Business Wire)

Planned COVID-19 testing locations at Los Angeles International Airport. (Photo: Business Wire)

“During this pandemic we understand just how crucial testing is, and we’re thrilled to be able to provide this service to passengers and employees alike at LAX, one of the largest airports and gateways of travel in the United States,” Paul Galvin, CEO and Chairman of SG Blocks noted. “We are very pleased to leverage SG Blocks’ technology and resources to provide a safer, more secure environment for traveling in 2020.”

Testing locations will include the Tom Bradley International Terminal, Terminal 2, and Terminal 6. Test collection will be available between the hours of 8:00 a.m. to 8:00 p.m., 7 days a week. Tests will cost $150 dollars and payment will be collected through a personal mobile device or tablet.

Clarity Mobile Ventures will be providing the PCR tests to passengers and employees with the testing expected to commence this week. Following this endeavor, LAX plans to open a full capacity, on-site rapid COVID-19 test laboratory in December across from Terminal 6. SG Blocks will serve as developers and Grimshaw Architects will serve as designers of the test site, with Clarity Lab Solutions being the primary operator of the facility. The full-service laboratory will offer both the PCR test as well as a rapid antigen test, with results available in just a few hours.

About SG Blocks, Inc.

SG Blocks, Inc. is a premier innovator in advancing and promoting the use of code-engineered cargo shipping containers for safe and sustainable construction. The firm offers a product that exceeds many standard building code requirements, and also supports developers, architects, builders and owners in achieving greener construction, faster execution, and stronger buildings of higher value. Each project starts with GreenSteel™, the structural core and shell of an SG Blocks building, and then customized to client specifications. For more information, visit www.sgblocks.com.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions and includes statements such as the PCR testing at the Tom Bradley International Terminal commencing this week. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to commence PCR testing at the Tom Bradley International Terminal this week as planned, the Company’s ability to position itself for future profitability, the Company’s ability to maintain compliance with the NASDAQ listing requirements, and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Media:

Rubenstein Public Relations

Christina Levin

Account Director

212-805-3029

[email protected]

Investors:

Stephen Swett

(203) 682-8377

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Packaging Air Other Construction & Property Transport Manufacturing Construction & Property Other Manufacturing

MEDIA:

Photo
Photo
Planned COVID-19 testing locations at Los Angeles International Airport. (Photo: Business Wire)
Posted on

Castellum in real estate transaction with the City of Gothenburg to enable future urban development

PR Newswire

GÖTEBORG, Sweden, Nov. 17, 2020 /PRNewswire/ — Castellum AB and the municipality of Gothenburg are carrying out a real estate transaction where Castellum is selling a property to the city in exchange for development rights in connection to Västlänken’s future Station Centralen.

“I see it as a typical example of a win-win, a good deal for both parties. We get to contribute to urban development in the city center while also offering the city an important piece of the puzzle in southern Gothenburg“, comments Henrik Saxborn, CEO of Castellum AB.

Due to intense development in the Frölunda-Högsbo-Sisjö area, the city has reviewed the needs for technical supply of both energy and waste management. The municipality does not own any suitable buildable land in connection with the area in question but has identified the undeveloped property Kobbegården 152:1 as suitable for this purpose. The property is owned by Castellum, and the municipality has a strategic interest in acquiring it.

Castellum was in favor of selling the property to the municipality of Gothenburg in exchange for another development project. In connection with the negotiations, the parties identified a building right located north of Nordstan in central Gothenburg for this purpose.

At Monday’s meeting of the property committee, it was decided that the municipality acquires the property Kobbegården 152:1 from Castellum, and that Castellum is at the same time allocated land allotment for a building right of approximately 20-30,000 sq.m. BTA for office and retail space including one of the entrances from Västlänken’s future Station Centralen.

“A very gratifying decision which also means that we can build in direct connection to our current properties at the northern end of Östra Nordstan”, states Mariette Hilmersson, CEO of Castellum Region West.

The agreed purchase price for the property Kobbegården 152:1 amounts to SEK 23.5 million.

For more information:

Mariette Hilmersson, CEO Castellum Region Väst, +46.31.7440902

Mattias Hedeberg, project developer Castellum Region Väst, +46.723.505313

About Castellum:

Castellum is one of Sweden’s largest listed real estate companies with a property value of SEK 98 billion. We are active in 17 Swedish growth regions as well as in Copenhagen and Helsinki. Every day, 250,000 people go to work in our premises. We develop flexible workplaces and logistics solutions in close proximity to city centres and with a lettable area of 4.3 million square meters. One of our sustainability goals is to be completely climate neutral by 2030. Castellum is the only Nordic real estate company selected by the Dow Jones Sustainability Index (DJSI). The Castellum share is listed on the Nasdaq Stockholm Large Cap.

Beyond expectations.
www.castellum.se

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/castellum/r/castellum-in-real-estate-transaction-with-the-city-of-gothenburg-to-enable-future-urban-development,c3238482

The following files are available for download:

 

Cision View original content:http://www.prnewswire.com/news-releases/castellum-in-real-estate-transaction-with-the-city-of-gothenburg-to-enable-future-urban-development-301174640.html

SOURCE Castellum

Posted on

Keurig Dr Pepper Announces Completion of Sale and Distribution for its Largest Shareholder; Mondelēz International’s (MDLZ) Position Reduced to Strategically Important Level

Maple to Sell and Distribute All Remaining Shares Not Owned by JAB

JAB to Remain Largest Shareholder, Focused on Long-Term Value Creation

MDLZ Ownership Stake Reduced to 8.4% with Continuation of Two KDP Board Seats

PR Newswire

BURLINGTON, Mass. and PLANO, Texas, Nov. 17, 2020 /PRNewswire/ — Keurig Dr Pepper Inc. (NASDAQ: KDP) today announced that JAB majority-owned subsidiary Maple Holdings B.V. (“Maple”) and MDLZ will sell an aggregate of 60 million shares through a secondary offering.  MDLZ will sell 40 million shares, bringing its stake to approximately 8.4% of KDP’s outstanding common stock, while Maple will sell 20 million shares for the benefit of its minority partners. 

Additionally, JAB indicated that JAB and Maple will convert the final portion of Maple’s minority partners’ shares into shares held directly in KDP and will distribute approximately 119 million shares of KDP common stock, representing approximately 8.5% of KDP’s outstanding common stock, currently held by Maple, to such minority holders.  The distribution relates to the minority interests in Maple which were held by over 100 JAB Consumer Fund (“JCF”) investors, comprised of mostly sovereign wealth funds, university endowments and family offices which invested alongside JAB over the last five years as part of its beverages investment strategy. Following these transactions, Maple will be renamed JAB Bevco and, through JAB Bevco, JAB and its affiliates will hold approximately 34% of KDP’s outstanding common stock.

Together, the transactions represent a major milestone step for KDP on its journey to becoming a widely-held modern beverage company.  Upon the completion of the transactions, KDP’s public float will increase to approximately 58%, as compared to approximately 13% at the time of the completion of the merger of Keurig Green Mountain and Dr Pepper Snapple Group in 2018.

CEO and Managing Partner of JAB, Olivier Goudet, stated, “Today marks the final sale on behalf of and distribution to our minority partners of Maple, who have been invested alongside us for the past five years.  We are very pleased to now place the remaining minority shares of Maple directly with our JCF partners who are like-minded, long-term focused investors.  We continue to be highly confident in KDP’s value creation potential and, therefore, JAB intends to remain a large, stable, long-term anchor investor supporting the growth of the company.”

Dirk Van de Put, CEO of MDLZ, commented, “This transaction brings our stake in KDP down to approximately 8.4%, a strategically important ownership level which allows us to retain two board seats and remain large investors in KDP.  We see significant upside in KDP and with this level of ownership, MDLZ’s shareholders will continue to share in the significant value creation that we believe lies ahead.”

Byron Trott, Chairman and CEO of BDT Capital Partners, a significant shareholder in KDP, stated, “We are strong believers in KDP, under the capable leadership of Bob Gamgort and his team.  We remain a committed long-term shareholder and plan to participate in the continued value creation that we are confident remains ahead for the company.”

Keurig Dr Pepper Chairman and CEO Bob Gamgort stated, “Today’s news signifies an important milestone in our company’s evolution. These transactions represent the realization of JCF’s investment that started with the JAB take-private of Keurig Green Mountain in early 2016, which ultimately enabled the creation of KDP.  We look forward to welcoming many of the JCF investors as long-term public shareholders of KDP and continuing to partner with JAB, MDLZ and BDT as long-term shareholders.”

Under the terms of the transactions, the distributed shares will be subject to a lock-up arrangment with Maple that will ratably apply for a period from six to twelve months. In addition, the remaining shares held by Maple and MDLZ and the shares held by BDT Capital Partners will be subject to a 90-day lock-up agreement with the underwriters. Maple and its affiliates, as well as MDLZ, intend to make the required filings with the SEC, including amendments to their respective existing Schedule 13Ds, upon the completion of the transactions.

Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC are acting as the underwriters for the proposed secondary offering.

The offering will be made only by means of an effective registration statement and a prospectus. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the proposed offering may be obtained from: Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing [email protected]. Morgan Stanley & Co. LLC at 180 Varick Street, 2nd Floor, New York, New York 10014, Attention: Prospectus Department. Copies of the preliminary prospectus supplement and the related prospectus may also be obtained free of charge from the website of the U.S. Securities and Exchange Commission (the “SEC”) at http://www.sec.gov.

The Company has previously filed with the SEC a registration statement (including a prospectus) on Form S-3 (File No. 333-233477) and a prospectus supplement, each dated August 27, 2019, as well as a preliminary prospectus supplement for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.


KDP Contacts


Tyson Seely (Investors)
T: 781-418-3352 / [email protected] 

Steve Alexander (Investors)
T: 972-673-6769 / [email protected] 

Katie Gilroy (Media)
T: 781-418-3345 / [email protected] 

About Keurig Dr Pepper
Keurig Dr Pepper (KDP) is a leading beverage company in North America, with annual revenue in excess of $11 billion and nearly 26,000 employees. KDP holds leadership positions in soft drinks, specialty coffee and tea, water, juice and juice drinks and mixers, and markets the #1 single serve coffee brewing system in the U.S. and Canada. The Company’s portfolio of more than 125 owned, licensed and partner brands is designed to satisfy virtually any consumer need, any time, and includes Keurig®, Dr Pepper®, Green Mountain Coffee Roasters®, Canada Dry®, Snapple®, Bai®, Mott’s®, CORE® and The Original Donut Shop®. Through its powerful sales and distribution network, KDP can deliver its portfolio of hot and cold beverages to nearly every point of purchase for consumers.  The Company is committed to sourcing, producing and distributing its beverages responsibly through its Drink Well. Do Good. corporate responsibility platform, including efforts around circular packaging, efficient natural resource use and supply chain sustainability.

FORWARD LOOKING STATEMENTS

Certain statements contained herein are “forward-looking statements” within the meaning of applicable securities laws and regulations. These forward-looking statements can generally be identified by the use of words such as “outlook,” “guidance,” “anticipate,” “expect,” “believe,” “could,” “estimate,” “feel,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “should,” “target,” “will,” “would,” and similar words, phrases or expressions and variations or negatives of these words, although not all forward-looking statements contain these identifying words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements regarding the estimated or anticipated future results of the combined company following the combination of Keurig Green Mountain, Inc. (“KGM”) and Dr Pepper Snapple Group, Inc. (“DPS” and such combination, the “transaction”), the anticipated benefits of the transaction, including estimated synergies and cost savings, the long-term merger targets, and other statements that are not historical facts. These statements are based on the current expectations of our management and are not predictions of actual performance.

These forward-looking statements are subject to a number of risks and uncertainties regarding the company’s business and the transaction and actual results may differ materially. These risks and uncertainties include, but are not limited to: (i) the impact the significant additional debt incurred in connection with the transaction may have on our ability to operate our business, (ii) risks relating to the integration of the KGM and DPS operations, products and employees into the combined company and assumption of certain potential liabilities of KGM and the possibility that the anticipated synergies and other benefits of the transaction, including cost savings, will not be realized or will not be realized within the expected timeframe, (iii) the impact of the global COVID-19 pandemic, and (iv) risks relating to the businesses and the industries in which our combined company operates. These risks and uncertainties, as well as other risks and uncertainties, are more fully discussed in the Company’s filings with the SEC, including our Annual Report on Form 10-K and subsequent filings. While the lists of risk factors presented here and in our public filings are considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Any forward-looking statement made herein speaks only as of the date of this document. We are under no obligation to, and expressly disclaim any obligation to, update or alter any forward-looking statements, whether as a result of new information, subsequent events or otherwise, except as required by applicable laws or regulations.

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/keurig-dr-pepper-announces-completion-of-sale-and-distribution-for-its-largest-shareholder-mondelz-internationals-mdlz-position-reduced-to-strategically-important-level-301174630.html

SOURCE Keurig Dr Pepper

Posted on

SAIC Wins Task Order Worth up to $973 Million to Help U.S. Customs and Border Protection Assess Threats From Travelers and Cargo Crossing the Border

SAIC Wins Task Order Worth up to $973 Million to Help U.S. Customs and Border Protection Assess Threats From Travelers and Cargo Crossing the Border

SAIC will innovate with cloud, agile delivery, and SecDevOps to promote U.S. border security

RESTON, Va.–(BUSINESS WIRE)–Science Applications International Corp. (NYSE: SAIC) was awarded a task order worth up to $973 million by U.S. Customs and Border Protection (CBP) to continue to operate, maintain, and enhance CBP’s cornerstone system for identifying travelers and cargo that present a potential security threat to the country.

The award for CBP’s Targeting and Analysis Systems Program Directorate (TASPD) Information Technology Operations and Maintenance, Upgrades, Updates, Modifications and Enhancements Services task order, made under the General Services Administration’s Alliant 2 contract, includes transition, a one-year base period of performance, four one-year option periods, and a six-month optional extension of services. The total award value including all options is $973 million.

“SAIC is proud of the trust the Department of Homeland Security and CBP have in our team’s ability to deliver mission-critical, innovative solutions,” said Bob Genter, president, Defense and Civilian Sector. “TASPD is a great example of how CBP has applied advanced technologies that continually deliver new capabilities to this 24x7x365 mission, while remaining responsive to the ever-changing national security landscape. SAIC will leverage our deep expertise in technologies including cloud, machine learning and AI, and SecDevOps to help CBP achieve its mission of enabling secure trade and travel.”

Under the task order, SAIC will continue to develop and maintain CBP’s targeting and analysis systems that integrate technologies and data in real-time, enabling CBP officers, analysts, and agents to flag shipments and travelers for additional examination and inspection. SAIC will deploy new capabilities such as cloud-based analytics and AI/machine learning to facilitate legitimate travel and trade, identify high-risk travelers and cargo faster, and enable CBP to maximize application of its skilled workforce.

SAIC will continue to enhance these systems in response to evolving technologies, threats, and mission requirements, and accelerate CBP capabilities to safeguard America. SAIC will evolve the TASPD portfolio from a collection of specialized applications to an ecosystem of capabilities and services shared across the enterprise using mission-driven agile processes and innovative technologies.

About SAIC

SAIC® is a premier Fortune 500® technology integrator driving our nation’s digital transformation. Our robust portfolio of offerings across the defense, space, civilian, and intelligence markets includes secure high-end solutions in engineering, IT modernization, and mission solutions. Using our expertise and understanding of existing and emerging technologies, we integrate the best components from our own portfolio and our partner ecosystem to deliver innovative, effective, and efficient solutions that are critical to achieving our customers’ missions.

We are 25,500 strong; driven by mission, united by purpose, and inspired by opportunities. Headquartered in Reston, Virginia, SAIC has pro forma annual revenues of approximately $7.1 billion.​​​​ For more information, visit saic.com. For ongoing news, please visit our newsroom.

Forward-Looking Statements

Certain statements in this release contain or are based on “forward-looking” information within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “guidance,” and similar words or phrases. Forward-looking statements in this release may include, among others, estimates of future revenues, operating income, earnings, earnings per share, charges, total contract value, backlog, outstanding shares and cash flows, as well as statements about future dividends, share repurchases and other capital deployment plans. Such statements are not guarantees of future performance and involve risk, uncertainties and assumptions, and actual results may differ materially from the guidance and other forward-looking statements made in this release as a result of various factors. Risks, uncertainties and assumptions that could cause or contribute to these material differences include those discussed in the “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Legal Proceedings” sections of our Annual Report on Form 10-K, as updated in any subsequent Quarterly Reports on Form 10-Q and other filings with the SEC, which may be viewed or obtained through the Investor Relations section of our website at saic.com or on the SEC’s website at sec.gov. Due to such risks, uncertainties and assumptions you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. SAIC expressly disclaims any duty to update any forward-looking statement provided in this release to reflect subsequent events, actual results or changes in SAIC’s expectations. SAIC also disclaims any duty to comment upon or correct information that may be contained in reports published by investment analysts or others.

Lauren Presti

703.676.8982

[email protected]

KEYWORDS: District of Columbia Virginia United States North America

INDUSTRY KEYWORDS: Contracts Defense

MEDIA:

Logo
Logo